Administration

DOSAGE RECOMMENDATION

In stroke and TBI Cerebrolysin^® should be administered as an adjunctive treatment to standard TBI care. The administration initiated optimally as soon as possible and continued throughout the rehabilitation phase.
For the treatment of dementia one therapy course corresponds to a therapy duration of 4 weeks (5 applications/week). The effectiveness of therapy can be increased by repeated courses after treatment-free periods of 2 - 3 months until no further benefit is observed.

Disorder	Daily dosage	Initiation of treatment	Duration of treatment
Stroke	20 - 50 ml	as soon as possible	10 - 21 days
Traumatic brain injury	20 - 50 ml	as soon as possible	7 - 30 days
Vascular dementia	10 - 30 ml	as soon as possible	1 cycle: 5 days weekly/4 weeks 2-4 cycles per year
Alzheimer's disease	20 - 50 ml	as soon as possible	1 cycle: 5 days weekly/4 weeks 2-4 cycles per year

ROUTE OF ADMINISTRATION

IV infusion	10ml - 50ml	diluted to at least 100ml total volume with Saline, Ringer solution or 5% glucose solution	Infuse within 15 minutes
To guarantee sterility, always use disposable one-way infusion sets and cannulas! Do not store the infusion solution, start the infusion as quickly as possibe after dilution! Cerebrolysin^® should not be mixed with balanced amino acid solutions, vitamins and cardiovascular medicinal products.

IV injection	up to 10ml	undiluted	inject slowly over 3 minutes
IM injection	up to 5ml	undiluted	inject slowly over 3 minutes
The IV or IM injection has to be administered immediately after opening the ampoule!

STERILITY ASPECTS

Special precautions to guarantee sterility must be taken during dilution and administration of Cerebrolysin^®:

Remove solution from ampoules immediately before use
Do not leave an open ampoule on the treatment table
Always use only disposable one-way IV infusions sets and cannulas
When Cerebrolysin^® is administered via a long-term IV catheter, the catheter has to be rinsed before and after the application with physiological sodium chloride solution
Pay special attention to recommended infusion/injection times page before

More information please find in our Dosage recommendation.

This information is based on the Austrian Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local EVER representative.